O'Leary Debra A, Cropp Eleanor, Isaac David, Desmond Paul V, Bell Sally, Nguyen Tin, Wong Darren, Howell Jessica, Richmond Jacqui, O'Neill Jenny, Thompson Alexander J
1Gastroenterology Department, St Vincent's Hospital Melbourne, 35 Victoria Parade, Fitzroy, VIC 3065 Australia.
2GP Liaison Department, St Vincent's Hospital Melbourne, 35 Victoria Parade, Fitzroy, VIC 3065 Australia.
Hepatol Med Policy. 2018 Jan 4;3:1. doi: 10.1186/s41124-017-0031-2. eCollection 2018.
The current model of care for the treatment of chronic hepatitis B (CHB) in Australia is through specialist Hepatology or Infectious Diseases clinics, and limited accredited primary care practices. Capacity is limited, and less than 5% of Australians living with CHB currently access therapy. Increasing treatment uptake is an urgent area of clinical need. Nucleos(t)ide analogue therapy is safe and effective treatment for CHB that is suitable for community prescribing. We have evaluated the success of a community-based model for the management of CHB in primary care clinics using a novel web-based clinical tool.
Using guidelines set out by the Gastroenterological Society of Australia, we developed an interactive online clinical management tool for the shared care of patients with CHB in primary care clinics, with remote oversight from tertiary hospital-based hepatologists and a project officer. We call this model of care the "B in IT" program. Suitable patients were referred from the specialist liver clinic back to primary care for ongoing management. Compliance with recommended appointments, pathology tests and ultrasounds of patients enrolled in "B in IT" was assessed and compared to that of the same patients prior to community discharge, as well as a matched control group of CHB outpatients continuing to attend a specialist clinic.
Thirty patients with CHB were enrolled in the "B in IT" program. Compliance with attending scheduled appointments within 1 month of the suggested date was 87% across all 115 visits scheduled. Compliance with completing recommended pathology within 1 month of the suggested date was 94% and compliance with completing recommended liver ultrasounds for cancer screening within 1 month of the suggested date was 89%. The compliance rates for visit attendance and ultrasound completion were significantly higher than the control patient group ( < 0.0001) and the "B in IT" patients prior to community discharge ( = 0.002 and = 0.039, respectively).
The "B in IT" program's novel web-based clinical tool supports primary care physicians to treat and monitor patients with CHB. This program promotes community-based care and increases system capacity for the clinical care of people living with CHB.
澳大利亚目前慢性乙型肝炎(CHB)的治疗模式是通过肝病专科或传染病专科诊所,以及有限的经认可的基层医疗机构。治疗能力有限,目前不到5%的澳大利亚慢性乙型肝炎患者能够接受治疗。提高治疗率是临床急需解决的领域。核苷(酸)类似物疗法是治疗慢性乙型肝炎的安全有效方法,适合在社区进行处方。我们使用一种新型的基于网络的临床工具,评估了基层医疗诊所中基于社区的慢性乙型肝炎管理模式的成效。
根据澳大利亚胃肠病学会制定的指南,我们开发了一种交互式在线临床管理工具,用于基层医疗诊所中慢性乙型肝炎患者的共享护理,并由三级医院的肝病专家和一名项目官员进行远程监督。我们将这种护理模式称为“乙肝信息化(B in IT)”项目。合适的患者从专科肝脏诊所转回基层医疗机构进行持续管理。评估了参与“乙肝信息化”项目的患者遵守推荐预约、病理检查和超声检查的情况,并与这些患者出院前以及继续在专科诊所就诊的慢性乙型肝炎门诊患者匹配对照组进行比较。
30名慢性乙型肝炎患者参与了“乙肝信息化”项目。在所有115次安排的就诊中,在建议日期后1个月内遵守预约就诊的比例为87%。在建议日期后1个月内完成推荐病理检查的比例为94%,在建议日期后1个月内完成推荐的肝脏超声癌症筛查的比例为89%。就诊出勤率和超声检查完成率的合规率显著高于对照组患者(<0.0001)以及“乙肝信息化”项目患者出院前的水平(分别为=0.002和=0.039)。
“乙肝信息化”项目基于网络的新型临床工具支持基层医疗医生治疗和监测慢性乙型肝炎患者。该项目促进了基于社区的护理,并提高了对慢性乙型肝炎患者临床护理的系统能力。